

REMARKS

Any fees that may be due in connection with the filing of this paper or with this application may be charged to Deposit Account No. 06-1050. If a Petition for Extension of Time is needed, this paper is to be considered such Petition.

The specification is amended to correct obvious typographical, spelling, and grammatical errors. Additionally, the specification is amended at page 11, line 3 to correct the fused sentence beginning at line 10 with "Exemplary of these diseases..." and ending at line 28 with "... these diseases or disorders." The fused sentence is amended to be two separate sentences, the first of which begins at line 10 with "Exemplary of these diseases..." and ends at line 27 with "... or glucocorticoid-induced glaucoma." The subject for the second sentence is taken directly from the dependent clause beginning at line 3 of the instant paragraph which recites, "effective amounts of the compounds or compositions containing therapeutically effective concentrations of the compounds". This clause is inserted at line 27 between "glaucoma" and "are administered" to form the second sentence.

The amendment at page 42, line 21 seeks to relocate the recitation, "In certain embodiments... R₇, R₈, R₉, and R₁₀ is not hydrogen" from the instant paragraph to page 44, line 5. The basis for this amendment is as follows. The paragraphs from page 35, line 17 through page 42, line 29 concern the structure of R₁ when R₁ is Formula II. Formula II, as found throughout the specification, for example on page 32, line 21, contains R groups numbered R₂-R₆ and does not contain R groups numbered R₇-R₁₀. However, Formula III as found throughout the specification, for example, on page 32, line 21 contains R groups numbered R₇-R₁₀ and is discussed in the section from page 42, line 30 through page 44, line 18. Therefore, the recitation which states, "In certain embodiments... R₇, R₈, R₉, and R₁₀ is not hydrogen" is moved from the section concerning Formula II on page 42, line 21 to the section concerning Formula III on page 44, line 5.

The amendment to the paragraph beginning at page 45, line 3 seeks to correct the group from which R₁₁ is selected by replacing list item "CONR₁₃R₁₄" with -CONR₁₄R₁₅-. The basis for this amendment is found throughout the specification, for example on page 4, lines 20-26 which recites: "R₁₁ is selected from hydrogen... aryloxyiminoalkyl, CONR₁₄R₁₅...".

The amendment to Table A, row 2, column 1 on page 54 seeks to correct the group variable "2" by specifically designating the variable as -R₂-. The basis for this amendment is found throughout the specification, for example on page 2, lines 19-24 which describes R₂

consistent with the Markush Groups defined for the entry “2” on page 54 in Table A, row 2, columns 2-5. Likewise, the variables in column 1 of Table A from page 54-58 are amended to specifically designate the variables as “R_x” where x is the integer from 3-17 (e.g., R_x = R₂, R₃, R₄... R₁₇). The bases for these amendments are found throughout the specification, for example on page 2, line 19 through page 5, line 28 which describes R₂-R₁₇ consistent with the Markush Groups defined in Table A, columns 2-5.

The amendment at page 59, lines 27-28 seeks to correlate the named compound, (Z)-5-(4'-ethylbenzylidene)-1,2-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline, with its corresponding compound number by replacing “38” with –36–. The basis for this amendment is found in the specification on page 134, lines 3-5 which correctly identifies (Z)-5-(4'-ethylbenzylidene)-1,2-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline as compound number 36.

The amendment at page 60, lines 1-2 seeks to correlate the named compound, (Z)-5-(2'-chloro-6'-fluorobenzylidene)1,2-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline, with its corresponding compound number by replacing “36” with –38–. The basis for this amendment is found in the specification on page 135, lines 3-5 which correctly identifies (Z)-5-(2'-chloro-6'-fluorobenzylidene)1,2-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline as compound number 38.

The amendment at page 62, lines 15-16 seeks to conform the name of Compound 79 with the name of Compound 79 as found on page 154, lines 5-7 of the specification by replacing “benzenecarbaldehyde” with –formylphenyl–. The amendment at page 63, lines 1-3 seeks to correct the name of Compound 85 by deleting the recitation “fluoro”. The basis for this amendment is found in the specification on page 157, lines 10-13 which correctly presents the name of Compound 85 without a fluoro group. Further support for this amendment is found on page 157, line 9 which shows the structure of Compound 85 does not contain a fluoro group.

The amendment at page 65, lines 6-11 seeks to correct the names of Compound 112 and Compound 113 by replacing “2,2-cyclohexyl-4-methyl” with –2,2,4-trimethyl–. The basis for the amendment to Compound 112 is found in the specification on page 172, line 4 which shows the structure of Compound 112 with two methyl groups at the second position of the quinoline ring as opposed to cyclohexyl groups. Likewise, the name of Compound 112 is also amended on page 172, lines 5-6 of the specification. The basis for the amendment to Compound 113 is found in the specification on page 172, line 14 which shows the structure

of Compound 113 with two methyl groups at the second position of the quinoline ring as opposed to cyclohexyl groups. Likewise, the name of Compound 113 is also amended on page 172, lines 15-16 of the specification.

The amendment at page 68, lines 13-15 seeks to conform the name of Compound 151 with the name of Compound 151 as found on page 192, lines 18-21 of the specification by replacing “piperidino” with –piperidine–. The amendment at page 72, lines 4-5 seeks to conform the name of Compound 192 with the name of Compound 192 as found on page 220, lines 17-19 of the specification by inserting an “E” stereodescriptor immediately preceding “2”.

The amendment at page 72, lines 11-13 seeks to correct the name of Compound 195 by inserting an open parenthesis symbol immediately preceding “Prop” and by inserting a closed parenthesis symbol immediately following “oxymethyl” such that the text now reads: “...(Prop-2"-enyloxymethyl)...”. The basis for this amendment is found on page 224, lines 11-13 of the specification which presents the correct name of Compound 195 with parentheses enclosing the recitation “Prop-2"-enyloxymethyl”.

The amendment at page 74, lines 9-11 seeks to correct the name of Compound 215 by removing an extraneous prime symbol, thus changing the first double prime three, “3’”, to a single prime three, –3’–. The basis for this amendment is found on page 237, lines 18-20 which presents the correct name of Compound 215 as “(Z)-5-(2'-(3'-(Thien...”.

The amendment at page 76, lines 25-27 seeks to correct the name of Compound 245 by removing an extraneous prime symbol, thus changing the double prime three, “3’”, to a triple prime three, –3’’–, such that the name now reads: “(Z)-5-(2'-(3'-(1"-Hydroxy-1"-(thien-3’’-yl...”. The basis for this amendment is found on page 258, lines 8-11 which presents the correct name of Compound 245 as “(Z)-5-(2'-(3'-(1"-Hydroxy-1"-(thien-3’’-yl...”.

The amendment at page 78, lines 1-3 seeks to correct the name of Compound 259 by removing two extraneous prime symbols, thus changing the double prime three “3’”, to a single prime three, –3’–; and changing the triple prime three, “3’’”, to a double prime three, –3’’–. The basis for this amendment is found on page 267, lines 1-3 which presents the correct name of Compound 259 as “(Z)-5-(2'-3'-(3"-Hydroxybutanoyl...”.

The amendment to Scheme VII on page 83, lines 25-35 seeks to clarify Structures 25 and 26 by elongating the bond between the –OR^G group and the carbon of the –CR^AR^B– moiety to accurately portray the absence of a covalent bond between the –OR^G group and the

fourth position of the thienyl ring. This amendment finds basis throughout the specification, for example, in the representative structures of Scheme VII on page 256, line 2 and line 24 of the specification which present separate, non-ring forming substituents on the phenyl group.

The amendment beginning at page 157, line 14 seeks to correct the name of a reactant used in Example 70 (General Method 2) by replacing "toluamide" with -toluene- such that the reactant name recites "5-bromo-2-(dimethylaminocarbonyl)toluene". This amendment finds basis in the recitation "aminocarbonyl" which specifies the amide substituent and renders "toluamide" redundant to the aminocarbonyl group. Furthermore, this amendment finds basis in the definition of General Method 2 on page 152, lines 1-11 which utilizes a reactant with a single amide moiety to afford the desired product.

The amendment at page 164, line 8 seeks to clarify the structure of Compound 98 by increasing the distance between the $-OCH_3$ and the N-methyl groups to accurately portray the absence of a covalent bond between the two benzylidene substituents. This amendment finds basis in the name of Compound 98 on page 164, lines 9-11 of the specification which designates the two separate, non-ring forming benzylidene substituents as 3-methoxy and 2-dimethylaminocarbonyl.

The amendment at page 204, lines 16-18 seeks to correct the R group numbers of Compound 166, Structure 10 of Scheme III, by replacing " R^{19} , R^{20} " with $-R^{14}$, $R^{15}-$. The basis for this amendment is found in Scheme III on page 79, line 16 which presents Structure 10 with R^{14} and R^{15} groups but without R^{19} or R^{20} groups.

The amendment beginning at page 218, line 17 seeks to remove the extraneous recitation " $R^A = Me$ " from the name of Compound 190, Structure 22 of Scheme V. The basis for this amendment is found in Scheme V on page 82, lines 4-19 which presents Structure 22 without an R^A group.

The amendment beginning at page 223, line 25 seeks to clarify the name of the deuterated NMR solvent by replacing "Acetone" with $-Acetone-d_6-$. This amendment finds basis throughout the specification, for example, on page 225, line 1 and on page 226, line 1 which utilize Acetone- d_6 as the NMR solvent.

The amendment beginning on page 230, line 3 seeks to remove an extraneous prime symbol from Structure 18 of Scheme V, thus changing the double prime three, " $3''$ ", to a single prime three, $-3'-$, such that the name now reads: "(Z)-5-(2'-(3'-Formyl...)". The basis for this amendment is found in Scheme V on page 82, lines 4-19 of the specification which presents Structure 18 with a formyl group at the third position of the thienyl (prime) ring.

Additional basis for this amendment is found on page 217, lines 24-25 of the specification which specifies Structure 18 of Scheme V as "(Z)-5-(2'-(3'-Formyl...)". Likewise, the amendments beginning on page 233, line 18; on page 234, line 22; and on page 241, lines 8-9 seek to remove an extraneous prime symbol such that the name reads: "(Z)-5-(2'-(3'-formyl...").

The amendment at page 232, lines 8-10 seeks to correct the reference to Compound 206, Structure 45 of Scheme XII, by replacing "XI" with -XII-. The basis for this amendment is found on page 87, lines 6-7 which presents Structure 45 within Scheme XII, as opposed to Scheme XI on page 86, lines 15-30 which does not contain a structure numbered "45". This amendment also seeks to clarify the R^A group by inserting -R^A = -CF₃- on page 232, lines 8-10. The basis for this amendment is found on page 232, lines 8-9 which designates a "2",2",2"-trifluoro" substituent on the ethyl moiety and corresponds to the R^A group of Structure 45 in Scheme XII on page 87, lines 6-7. Furthermore, this amendment seeks to correct obvious capitalization errors by inserting an upper case 'F' in "Fluoro" and by using a lower case 't' in "trifluoro".

The amendment at page 234, lines 4-6 seeks to correct the description of the R^A group of Compound 209, Structure 20 in Scheme V, by replacing "1-hydroxyallyl" with -vinyl-. The basis for this amendment is found by comparing the structure of Compound 209 on page 234, line 2 with Structure 20 of Scheme V on page 82, lines 4-19. The portion of Compound 209's structure on page 234 which correlates with R^A of Structure 20 in Scheme V is -CH=CH₂ (vinyl) instead of -CH(OH)-CH=CH₂ (1-hydroxyallyl).

The amendment at page 238, lines 10-12 seeks to remove an extraneous prime symbol from Compound 216 thus changing the double prime three, "3'", to a single prime three, -3'-, such that the name now reads: "(Z)-5-(2'-(3'-(Cyclohexanecarbonyl...". The basis for this amendment is found in the structure of Compound 216 on page 238, line 8 of the specification which presents a cyclohexanecarbonyl group at the third position of the thienyl (prime) ring.

The amendment at page 239, lines 16-18 seeks to correct the R group numbers of Compound 218, Structure 33 of Scheme IX, by replacing "R¹⁹=H, R²⁰=phenyl" with -R¹⁴=H, R¹⁵=phenyl-. The basis for this amendment is found in Scheme IX on page 84, line 35 which presents Structure 33 with R¹⁴ and R¹⁵ groups but without R¹⁹ or R²⁰ groups. Likewise, Compound 218 on page 239, lines 16-18; Compound 219 on page 240, lines 17-19; Compound 220 on page 241, lines 3-6; Compound 221 on page 241, lines 18-21; Compound

222 on page 242, lines 8-11; and Compound 223 on page 243 are also amended to correct the R group numbers by replacing "R¹⁹" with -R¹⁴- and by replacing "R²⁰" with -R¹⁵-.

The amendment beginning on page 247, line 1 seeks to correct the name of Structure 21 in Scheme V by removing an extraneous prime symbol, thus changing the double prime three, "3'", to a single prime three, -3'-, such that the name now reads: "(Z)-5-(2'-(3'- (trifluoroacetyl...)". The basis for this amendment is found in the name of Structure 21 on page 247, lines 1-3 of the specification which correctly designates the first three as single prime.

The amendment at page 249, lines 9-11 seeks to correct the R group numbers of Compound 232, Structure 30 of Scheme VIII, by replacing "R¹⁹, R²⁰" with -R¹⁴, R¹⁵-. The basis for this amendment is found in Scheme VIII on page 84, lines 3-19 which presents Structure 30 with R¹⁴ and R¹⁵ groups but without R¹⁹ or R²⁰ groups. Likewise, Compound 232 on page 249, line 26; Compound 248 on page 260, lines 5-8 and on page 260, line 18; Compound 249 on page 261, lines 3-5; Compound 250 on page 261, lines 16-20; Compound 251 on page 262, lines 7-9; Compound 252 on page 262, lines 19-22; Compound 253 on page 263, lines 9-12; Compound 254 on page 264, lines 1-4; and Compound 256 on page 264, lines 13-16 are also amended to correct the R group numbers by replacing "R¹⁹" with -R¹⁴- and by replacing "R²⁰" with -R¹⁵-.

The amendment beginning at page 251, line 19 seeks to correct the reference to the afforded compound of Example 209 by replacing "162" with -234- at line 23. The basis for this amendment is found on page 251, lines 17-18 which designates Compound 234 as the product afforded in Example 209.

The amendment beginning at page 266, line 4 seeks to correct the name of Structure 50 of Scheme XIII by replacing "butan" with -propan- at line 14. The basis for this amendment is found on page 266, lines 4-6 which correctly names Structure 50 of Scheme XIII as "...phenylpropanoyl...".

Claims 1-52, 54-84, and 86-136 are pending. Claims 1, 2, 7, 13, 15, 16, 23, 42, 46, 60, 62, 63, 76, 84, 86, 89, 107-112, 115, and 117 are amended herein. Claim 53 duplicates Claim 52, thus Claim 53 is cancelled herein without prejudice or disclaimer. Claims 85 and 137 were previously cancelled in the preliminary amendment filed on August 17, 2006. Claims 1, 2, 13, 15, 16, 23, 62, 63, and 76 are amended to correct obvious typographical, spelling, and grammatical errors.

Claim 7 is amended to depend solely from Claim 1 by deleting the recitation “and 6”, thereby eliminating multiple claim dependency. Claim 42 is amended to correct an obvious punctuation error by relocating the period from the left-hand side of the structures to the right-hand side of the structures. Claim 46 is amended to correct an obvious punctuation error by inserting a comma between the first two structures of the instant claim.

Claim 60 is amended by replacing the group from which R₁₁ is selected by replacing list item “CONR₁₃R₁₄” with “CONR₁₄R₁₅”. The basis for this amendment is found throughout the specification, for example on page 4, lines 20-23 which recites: “R₁₁ is selected from hydrogen... aryloxyiminoalkyl, CONR₁₄R₁₅...”.

Claims 84, 86, and 89 are amended to correct obvious punctuation errors by inserting commas between the first and second, and between the second and third structures. Claim 84 is also amended by inserting “or” between the third and fourth structures, and by inserting a comma following the last structure, to render the claim grammatically correct.

Claims 107 and 108 are amended to correlate the named compound, (Z)-5-(4'-ethylbenzylidene)-1,2-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline, with its corresponding compound number by replacing “38” with –36–. The basis for this amendment is found in the specification on page 134, lines 3-5 which correctly identifies (Z)-5-(4'-ethylbenzylidene)-1,2-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline as compound number 36.

Claims 107 and 108 are amended to correlate the named compound, (Z)-5-(2'-chloro-6'-fluorobenzylidene)1,2-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline, with its corresponding compound number by replacing “36” with –38–. The basis for this amendment is found in the specification on page 135, lines 3-5 which correctly identifies (Z)-5-(2'-chloro-6'-fluorobenzylidene)1,2-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline as compound number 38.

Claims 107, 108 and 117 are amended to correct the obvious spelling error in the name of Compound 42 by replacing “methylidiene” with –methylidene–. Likewise, the spelling of “methylidene” is corrected in the names of Compound 97 and Compound 120 in Claims 107, 108, and 109. The spelling of “methyldiene” is also corrected in the names of Compound 123 and Compound 125 in Claims 107 and 108.

Claims 107 and 108 are amended to correct an obvious typographical error in Compound 67 by inserting a space between “quinoline” and “(compound 67)”. Claims 107 and 108 are also amended for clarity by conforming the name of Compound 79 with the name

of Compound 79 as found on page 154, lines 5-7 of the specification by replacing “benzenecarbaldehyde” with –formylphenyl–.

Claims 107 and 108 are amended to correct the name of Compound 85 by deleting the recitation “fluoro”. The basis for this amendment is found in the specification on page 157, lines 10-13 which correctly presents the name of Compound 85 without a fluoro group. Further support for this amendment is found on page 157, line 9 which shows the structure of Compound 85 does not contain a fluoro group.

Claims 107 and 108 are amended to correct the spelling error in the name of Compound 96 by replacing “morpholine” with –morpholino–. Claims 107 and 108 are also amended to correct the obvious spelling error in the name of Compound 111 by replacing “naphyl” with –naphthyl–.

Claims 107 and 108 are amended to correct the names of Compound 112 and Compound 113 by replacing “2,2-cyclohexyl-4-methyl” with –2,2,4-trimethyl–. The basis for the amendment to Compound 112 is found in the specification on page 172, line 4 which shows the structure of Compound 112 with two methyl groups at the second position of the quinoline ring as opposed to cyclohexyl groups. The basis for the amendment to Compound 113 is found in the specification on page 172, line 14 which shows the structure of Compound 113 with two methyl groups at the second position of the quinoline ring as opposed to cyclohexyl groups.

Claims 107, 108, and 110 are amended to correct the obvious spelling error in the name of Compound 126 by replacing “dichlo” with –dichloro–. Claims 107 and 115 are amended for clarity by conforming the name of Compound 151 with the name of Compound 151 as found on page 192, lines 18-21 of the specification by replacing “piperidino” with –piperidine–.

Claims 107 and 111 are amended for clarity by conforming the name of Compound 192 with the name of Compound 192 as found on page 220, lines 17-19 of the specification by inserting an “E” stereodescriptor immediately preceding “2”. Claims 107 and 115 are amended for clarity by conforming the name of Compound 195 with the name of Compound 195 as found on page 224, lines 11-13 by inserting an open parenthesis symbol immediately preceding “Prop” and by inserting a closed parenthesis symbol immediately following “oxymethyl” such that the text reads: “...(Prop-2"-enyloxymethyl)...”.

Claims 107, 111, and 115 are amended to correct the name of Compound 215 by removing an extraneous prime symbol, thus changing the first double prime three, “3””, to a

single prime three, $-3'$ –, such that the name now reads: “(Z)-5-(2’-(3’-(Thien...”’. The basis for this amendment is found on page 237, lines 18-20 of the specification which correctly presents the name of Compound 215 as “(Z)-5-(2’-(3’-(Thien...”’.

Claims 107 and 115 are amended to correct the name of Compound 245 by removing an extraneous prime symbol, thus changing the double prime three, “3””, to a triple prime three, $-3''$ –, such that the name now reads: “(Z)-5-(2’-(3’-(1”-Hydroxy-1”-(thien-3”-yl...”’. The basis for this amendment is found on page 258, lines 8-11 of the specification which correctly presents the name of Compound 245 as “(Z)-5-(2’-(3’-(1”-Hydroxy-1”-(thien-3”-yl...”’.

Claims 107 and 115 are amended to correct the name of Compound 259 by removing two extraneous prime symbols, thus changing the double prime three “3””, to a single prime three, $-3'$ –; and changing the triple prime three, “3””, to a double prime three, $-3''$ –. The basis for this amendment is found on page 267, lines 1-3 of the specification which correctly presents the name of Compound 259 as “(Z)-5-(2’-3’-(3”-Hydroxybutanoyl...”’.


Claim 112 is amended to correct the name of Compound 206 by inserting $-4'$ -Fluoro-- immediately preceding “2” and by replacing the first letter of “Trifluoro” with a lower case $-t-$. The basis for this amendment is found on page 232, lines 8-9 of the specification which correctly presents the name of Compound 206 as “ (\pm) -(Z)-5-(4'-fluoro-2’-(2”,2”,2"-trifluoro...”’.

Accordingly, no new matter has been added to the specification or to the claims.

* * *

Entry of this amendment and examination of the application are respectfully requested.

Respectfully submitted,


Stephanie Seidman
Reg. No. 33,779

Attorney Docket No. 18202-027US1 / 1110US

Address all correspondence to:
Stephanie Seidman
Fish & Richardson P.C.
12390 El Camino Real
San Diego, California 92130
Telephone: (858) 678-4777
Facsimile: (202) 626-7796
email: seidman@fr.com
10668814.doc